Phase III EV-302 Trial Data Lead to sNDA Submission for Padcev/Keytruda Combo for Urothelial Cancer
January 31st 2024The Padcev/Keytruda combination produced statistically significant and clinically meaningful improvements to survival compared to platinum-containing chemotherapy in first-line treatment of adults with previously untreated locally advanced or metastatic urothelial cancer.
Phase III KEYNOTE-564 Trial Data Show Keytruda Improves Survival in Renal Cell Carcinoma
January 29th 2024Trial shows Keytruda improved overall survival by 38% compared with placebo in in patients with renal cell carcinoma at intermediate-high or high risk of recurrence after nephrectomy or nephrectomy and resection of metastatic lesions.
Antibody Drug Conjugate Enhertu Gets FDA Priority Review for Solid Tumors
January 29th 2024The Priority Revew designation was based on findings from the ongoing, global, multicenter, multi-cohort, open-label Phase II DESTINY-PanTumor02 trial of of Enhertu for patients with previously treated HER2-expressing tumors, including biliary tract cancer, bladder cancer, cervical cancer, endometrial cancer, ovarian cancer, pancreatic cancer, and other tumor types.
Micah Lieberman of ClinEco and CHI Speaks on the SCOPE Conference
January 26th 2024In an interview with ACT editor, Andy Studna, Lieberman, Executive Director, Conferences (CHI) & Co-Founder, VP, Community and Business Development (ClinEco) discusses the Summit for Clinical Ops Executives (SCOPE) conferences in Europe and the US.